Press release
Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, Coherus BioSciences, Gyros Protein Technologies AB, Fresenius Kabi, Viatris, Amgen Inc.
Psoriasis Biosimilars Market
According to the latest research by InsightAce Analytic, the Psoriasis Biosimilars Market is valued at US$ 8.5 billion in 2023, and it is expected to reach US$ 19.3 billion by 2031, with a CAGR of 10.9% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2891
A biologic therapy is designated as a biosimilar when it demonstrates high similarity to an FDA-approved reference product used in the treatment of psoriasis. Psoriasis is a chronic autoimmune skin disorder marked by rapid skin cell proliferation, inflammation, and scaling. Following the expiration of patents on originator biologics, biosimilars are developed to adhere to stringent regulatory standards concerning safety, efficacy, and quality.
The global psoriasis biosimilars market is experiencing notable growth, primarily driven by the increasing prevalence of psoriasis and the growing demand for cost-effective therapeutic alternatives. Additionally, heightened awareness among healthcare professionals and patients regarding the clinical effectiveness and affordability of biosimilars is significantly contributing to their broader adoption and market expansion.
List of Prominent Players in the Psoriasis Biosimilars Market:
• Merck KGaA
• Coherus BioSciences
• Gyros Protein Technologies AB
• Fresenius Kabi
• Viatris
• Amgen Inc
• Samsung Bioepis Co., Ltd.
• Hoffmann-La Roche Ltd
• Celltrion
• Pfizer Inc.
• Samsung Bioepis
• Sandoz
• Novartis International AG
• Reddy's Laboratories
• GenScript
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
The escalating costs of healthcare are prompting the adoption of biosimilars as cost-effective alternatives to originator biologics, offering comparable therapeutic efficacy at reduced prices. This shift has proven particularly beneficial for psoriasis patients, as biosimilars have shown effectiveness in symptom management and quality-of-life improvement. Payers and healthcare providers are increasingly inclined toward these more affordable solutions. Moreover, growing efforts to enhance healthcare accessibility in developing economies are further boosting demand. Government-backed initiatives promoting the use of biosimilars, especially in regions with a high prevalence of psoriasis, are accelerating market penetration. Additionally, the rising number of biosimilar approvals by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is reinforcing market growth.
Challenges:
One of the key challenges facing the psoriasis biosimilars market is regulatory uncertainty associated with product development, approval, and commercialization. Inconsistencies in regulatory frameworks, evolving guidelines, and complexities in proving biosimilarity and interchangeability present significant hurdles. These factors create an unpredictable environment that can delay product launches and limit patient access to cost-effective therapies, thereby hindering the market's full potential.
Regional Trends:
North America is projected to maintain a dominant position in the psoriasis biosimilars market, supported by its advanced biotechnology infrastructure and leadership in pharmaceutical innovation. Concurrently, the Asia-Pacific region is emerging as a high-growth area, driven by increased investment in biopharmaceutical R&D and the adoption of cutting-edge technologies for biosimilar development. The region's substantial psoriasis burden is contributing to rising demand for effective and affordable treatments, positioning biosimilars as essential components in the management of chronic dermatological conditions.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2891
Recent Developments:
• In July 2023, Coherus introduced YUSIMRYTM, a biosimilar of Humira®, priced at $995 per carton in the United States. YUSIMRY, sanctioned by the United States Food and Drug Administration (FDA) in 2021, is a tumour necrosis factor (TNF) inhibitor indicated for alleviating the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, as well as for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.
Segmentation of Psoriasis Biosimilars Market-
By Drug Class-
• TNF-alpha inhibitors
o Infliximab
o Etanercept
o Adalimumab
• Other biosimilars
By Route of Administration-
• Subcutaneous
• Intravenous
• Oral
• Topical
By Indication-
• Plaque psoriasis
• Psoriatic arthritis
• Other types
By Distribution Channel-
• Hospital pharmacies
• Retail pharmacy chains
• Online pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/psoriasis-biosimilars-market/2891
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psoriasis Biosimilars Market Key Players Analysis- Merck KGaA, Coherus BioSciences, Gyros Protein Technologies AB, Fresenius Kabi, Viatris, Amgen Inc. here
News-ID: 4072018 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Fuel Cell Commercial Vehicle Market Exclusive Report on Current Trends and Futur …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Fuel Cell Commercial Vehicle Market Size, Share & Trends Analysis Report By Vehicle (Light commercial vehicles, Medium commercial vehicles, Heavy commercial vehicles), Fuel Cell Technology (Proton exchange membrane, Alkaline fuel cells, Solid oxide fuel cells), Range (Short-range, Medium-range, Long-range), End User (Public transit, Construction and mining, Logistics & transportation, Others)- Market Outlook And Industry Analysis…
Zero Emission Vehicle Market is on an Upward Growth Curve
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Zero Emission Vehicle Market"-, By Vehicle Class (Passenger Cars, Commercial Vehicles, Two-Wheeler), By Drive (Front Wheel, Rear Wheel, All-Wheel), By Top Speed (Less than 100 Mph, 100 to 125 Mph, more than 125 Mph), By Vehicle Type (Battery Electric Vehicles (BEVs), Fuel Cell Electric Vehicles (FCEVs)), and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To…
Hydrogen Vehicles Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Hydrogen Vehicles Market"-, By Technology (PAFC (Phosphoric Acid Fuel Cell), DMFC (Direct Methanol Fuel Cell), and PEMFC (Proton Exchange Membrane Fuel Cell)), By Fuel Capacity (Up to 75 kW, 76 to 100 kW, 101 to 150 kW, Above 150 kW), By Vehicle Category (Passenger, Commercial) Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast…
Autonomous Mobility Ecosystem Market Future Trends and Scope Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Autonomous Mobility Ecosystem Market"-, By Type (People Move Autonomously, Cargo Moves Autonomously), By Application (Civil, Defense, Transportation and Logistics, Others), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."
The Autonomous Mobility Ecosystem Market is estimated to exhibit a CAGR of 34.8% during the forecast period.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/2641…
More Releases for Psoriasis
Prevalence Of Psoriasis Driving Market Growth: Key Factor Driving The Growth In …
The Psoriasis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Psoriasis Market Size During the Forecast Period?
The psoriasis market has seen rapid growth in recent years. It will increase from $26.56 billion in 2024 to $29.5 billion in 2025, at a…
Major Market Shift in Psoriasis Industry: Combination Therapy Is An Emerging Tre …
What Is the Forecasted Market Size and Growth Rate for the Psoriasis Market?
The market scope for psoriasis has seen substantial growth in the past years. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, with a compound annual growth rate (CAGR) of 11.1%. Factors such as epidemiology, patient awareness and education, along with healthcare infrastructure and access have contributed to the growth in the…
Major Market Shift in Psoriasis Industry: Combination Therapy Is An Emerging Tre …
What Is the Forecasted Market Size and Growth Rate for the Psoriasis Market?
The market scope for psoriasis has seen substantial growth in the past years. It is projected to escalate from $26.56 billion in 2024 to $29.5 billion in 2025, with a compound annual growth rate (CAGR) of 11.1%. Factors such as epidemiology, patient awareness and education, along with healthcare infrastructure and access have contributed to the growth in the…
Plaque Psoriasis to Hold 85% Share of Psoriasis Drugs Market through 2031
Psoriasis is a chronic inflammatory skin disease that occurs due to genetic disposition and environmental factors. Psoriasis is a systemic disease associated with psychological, metabolic, arthritic, and cardiovascular comorbidities. On an average, psoriasis affects around 2 - 3% of the population globally.
Plaque psoriasis, being the number one and most common indication, held nearly 85% share of the US$ 11.37 Bn psoriasis drugs market in 2021, with the market estimated to…
Psoriasis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Psoriasis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Psoriasis - Pipeline Review, H1 2017, provides an overview of the Psoriasis (Immunology) pipeline landscape.
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared up…
Global Psoriasis Market with Focus on Plaque Psoriasis: Outlook to 2020
Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It…
